Selected article for: "genome sequence and SARS sequence"
Author: Yang, Dongki
Title: Application of Nanotechnology in the COVID-19 Pandemic
  • Cord-id: 35106b55
  • Document date: 2021_1_26
    • ID: 35106b55
    Snippet: COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the
    Document: COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the genome sequence and protein structure have been published in a short period, making research and development for prevention and treatment relatively easy. In addition, intranasal drug delivery has proven to be an effective method of administration for treating viral lung diseases. In recent years, nanotechnology-based drug delivery systems have been applied to intranasal drug delivery to overcome various limitations that occur during mucosal administration, and advances have been made to the stage where effective drug delivery is possible. This review describes the accumulated knowledge of the previous SARS-CoV and MERS-CoV infections and aims to help understand the newly emerged SARS-CoV-2 infection. Furthermore, it elucidates the achievements in developing COVID-19 vaccines and therapeutics to date through existing approaches. Finally, the applicable nanotechnology approach is described in detail, and vaccines and therapeutic drugs developed based on nanomedicine, which are currently undergoing clinical trials, have presented the potential to become innovative alternatives for overcoming COVID-19.

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • accurate diagnosis and additional study: 1
    • accurate diagnosis and live inactivated: 1
    • accurate diagnosis and lymph node: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and live inactivated: 1
    • acute ards respiratory distress syndrome and live virus: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and low apparent: 1
    • acute ards respiratory distress syndrome and low dose patient: 1, 2
    • acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
    • acute ards respiratory distress syndrome and low toxicity: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung deliver: 1, 2
    • acute ards respiratory distress syndrome and lung inhalation: 1, 2, 3
    • acute ards respiratory distress syndrome and lung kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute ards respiratory distress syndrome and lung kidney disease: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lung surfactant: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung therapeutic deliver: 1
    • acute ards respiratory distress syndrome and lymph node: 1, 2